NEU 3.23% $13.11 neuren pharmaceuticals limited

Another reason for getting ROW done and dusted is that it...

  1. 2,851 Posts.
    lightbulb Created with Sketch. 600
    Another reason for getting ROW done and dusted is that it removes an issue that is surely taking a considerable amount of JP's (and others) valuable time.

    If Neuren is to maximise the potential of NNZ-2591 they need to have their key human resources really focused on the options that will be possible if the current phase 2 trials are successful.

    Hundreds of millions of dollars of shareholders investments (possibly more) might be at stake in just a few months time.
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.